Invasiveness and metastasis are the most common characteristics of non small cell lung cancer (NSCLC) and causes of tumour−related morbidity and mortality. Mitogen−activated protein kinases (MAPKs) signalling pathways have been shown to play critical roles in tumorigenesis. However, the precise pathological role(s) of mitogen−activated protein kinase phosphatase−1 (MKP−1) in different cancers has been controversial such that the up−regulation of MKP−1 in different cancers does not always correlate to a better prognosis. In this study, we showed that the induction of MKP−1 lead to a significant retardation of proliferation and metastasis in NSCLC cells. We also established that rosiglitazone (a PPARgamma agonist) elevated MKP−1 expression level in NSCLC cells and inhibited tumour metastasis.
»
03/12/10